Physician profile
Scott A Griffith
NPI 1063411122
$4,091.73
in general payments reported to CMS, 2019-2025
24 companies · $646 in 2025
The $646 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $313 · 2021: $529 · 2022: $450 · 2023: $547 · 2024: $592 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $705.86 | 2019-2022 | |
| Abbvie INC. | $471.59 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $426.35 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $326.65 | 2019-2021 | |
| Sight Sciences, INC. | $272.58 | 2024-2025 | Omni Surgical System |
| Alcon Vision LLC | $249.46 | 2019-2024 | Rocklatan, Argos, Dailies |
| Tarsus Pharmaceuticals, INC. | $226.73 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $188.48 | 2019-2025 | Cequa |
| Horizon Therapeutics Plc | $176.40 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $170.21 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $163.92 | 2021-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $124.97 | 2019 | |
| Aerie Pharmaceuticals, INC. | $120.90 | 2019 | |
| Omeros Corporation | $120.75 | 2019 | |
| Rxsight INC | $71.38 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $71.06 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $34.45 | 2019-2021 | |
| Shire North American Group INC | $31.43 | 2019 | |
| Amgen INC. | $27.68 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $26.07 | 2023 | Tecnis Simplicity |
| Rayner Intraocular Lenses Limited | $25.91 | 2025 | Omidria |
| Lombart Brothers, INC. | $25.23 | 2019 | |
| Harrow Eye, LLC | $19.27 | 2024 | Ilevro |
| Ocular Therapeutix, INC. | $14.40 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.